NASDAQ:NVCRNovocure Stock Price, Forecast & News

Novocure's stock was trading at $67.38 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NVCR shares have decreased by 10.0% and is now trading at $60.65. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Novocure.

Novocure is scheduled to release its next quarterly earnings announcement on Thursday, July 30th 2020. View our earnings forecast for Novocure.

Novocure will be holding an earnings conference call on Thursday, July 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Novocure Ltd (NASDAQ:NVCR) released its earnings results on Thursday, April, 30th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.03 by $0.01. The medical equipment provider earned $101.83 million during the quarter, compared to analysts' expectations of $102.10 million. Novocure had a return on equity of 4.39% and a net margin of 2.34%. The company's revenue for the quarter was up 38.9% on a year-over-year basis. During the same period last year, the company earned ($0.13) earnings per share. View Novocure's earnings history.

8 brokerages have issued 1 year target prices for Novocure's stock. Their forecasts range from $58.00 to $90.00. On average, they expect Novocure's share price to reach $79.00 in the next twelve months. This suggests a possible upside of 30.3% from the stock's current price. View analysts' price targets for Novocure.

Media coverage about NVCR stock has trended negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Novocure earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned media stories about the medical equipment provider a news buzz of 7.0 out of 10, meaning that recent press coverage is likely to have an impact on the company's share price in the near future. View the latest news about Novocure.

Novocure saw a decline in short interest in June. As of June 15th, there was short interest totaling 3,730,000 shares, a decline of 5.6% from the May 31st total of 3,950,000 shares. Based on an average daily volume of 957,600 shares, the days-to-cover ratio is currently 3.9 days. Approximately 4.5% of the shares of the stock are sold short. View Novocure's Current Options Chain.

Some companies that are related to Novocure include Teleflex (TFX), Insulet (PODD), ABIOMED (ABMD), Hill-Rom (HRC), Penumbra (PEN), Tandem Diabetes Care (TNDM), Globus Medical (GMED), Haemonetics (HAE), Integra Lifesciences (IART), Nevro (NVRO), ICU Medical (ICUI), Inovio Pharmaceuticals (INO), Irhythm Technologies (IRTC), NuVasive (NUVA) and Merit Medical Systems (MMSI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novocure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners, L.P (CLMT), Two Harbors Investment (TWO), Blackrock Capital Investment (BKCC), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), NVIDIA (NVDA), Washington Prime Group (WPG) and Roper Technologies (ROP).

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVCR stock can currently be purchased for approximately $60.65.

Novocure has a market capitalization of $6.09 billion and generates $351.32 million in revenue each year. The medical equipment provider earns $-7,230,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis.

The official website for Novocure is www.novocure.com.

Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]